Juvenescence: Investing in the Age of Longevity

Juvenescence examines the scientific and investment opportunities emerging from longevity research and anti-aging technologies. The authors provide an overview of current developments in biotechnology, regenerative medicine, and other fields that may extend human lifespan. The book breaks down complex biological concepts and research into accessible explanations for non-scientific readers. Through interviews with researchers and industry experts, it presents the key players and companies working to combat age-related diseases and slow the aging process itself. The analysis extends beyond science to explore the economic and investment implications of extended human lifespans. It outlines potential ways for investors to participate in what the authors project will become a multi-trillion dollar industry. This work sits at the intersection of scientific exploration and market analysis, raising questions about the societal impact of dramatically increased lifespans. The authors present both the promises and challenges of a "post-aging" world while maintaining a focus on practical investment considerations.

Readers describe this book as a practical guide to longevity investing that balances technical detail with accessibility. The book provides specific company recommendations and investment opportunities in the longevity sector. Liked: - Clear explanations of complex biotech concepts - Actionable investment advice with company profiles - Comprehensive overview of longevity technologies - Business-focused rather than purely scientific approach Disliked: - Some company recommendations became outdated quickly - Investment advice section could be more detailed - Technical terms can be overwhelming for non-scientific readers - Focus primarily on UK/European markets Ratings: Amazon: 4.3/5 (87 reviews) Goodreads: 4.1/5 (89 ratings) Notable reader comment: "The book succeeds as an introduction to longevity investing but falls short as a detailed investment guide. Their company analysis lacks the depth needed for serious investors." - Amazon reviewer Some readers noted the book serves better as a primer on longevity science than as an investment manual.

Lifespan by David A. Sinclair A Harvard researcher presents biological discoveries and emerging technologies that target aging as a medical condition to be treated.

The Longevity Code by Kris Verburgh This guide connects scientific research with practical interventions to slow cellular aging through nutrition, exercise, and lifestyle modifications.

Spring Chicken by Bill Gifford A deep dive into longevity research explores both legitimate scientific breakthroughs and questionable anti-aging claims in the quest for extended life.

The Telomere Effect by Elizabeth Blackburn Nobel Prize winner Blackburn explains how telomeres influence aging and presents evidence-based methods to protect these cellular structures.

100 Plus by Sonia Arrison An examination of how biotechnology advances will reshape human longevity and transform society, economics, and human relationships.

🧬 Jim Mellon, dubbed "Britain's Warren Buffett," conducted over 100 interviews with scientists, doctors, and biotech entrepreneurs before writing this comprehensive guide to longevity investing. 🔬 The book predicts that by 2040, the average human lifespan could extend to 100 years through advances in regenerative medicine, gene therapy, and senolytic drugs. 🌟 Juvenescence Limited, the biotech company co-founded by Jim Mellon in 2016, has grown to be worth over $500 million and invests in multiple longevity-focused ventures. 🧪 The authors identify "longevity escape velocity" - the point at which science can add more than one year of life expectancy per year - as a crucial milestone that could be reached by 2035. 💰 The book estimates that the longevity industry could be worth over $20 trillion by 2025, potentially surpassing the size of the current healthcare sector.